Related Experiment Video
Updated: Aug 26, 2025
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Clinical and laboratory responses to tigecycline in children
Kaan Aslan1, Ömer Kiliç2, Eylem Kiral3
1Department of Pediatrics, Eskişehir Osmangazi University Medical Faculty, Eskişehir, Turkey.
Insights
Tigecycline shows promise as a safe treatment for multidrug-resistant bacterial infections in children. This study found low side effect rates, suggesting its potential as a salvage therapy when other options are limited.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Resistance
- Pharmacology
Background:
- The global rise in multidrug-resistant bacterial infections presents a significant challenge, particularly in pediatric intensive care.
- Tigecycline, a broad-spectrum antibiotic, is a potential option for severe nosocomial infections, but data in children are scarce.
Purpose of the Study:
- To evaluate the efficacy and safety of tigecycline in pediatric patients with resistant bacterial infections.
- To highlight tigecycline as a potential therapeutic alternative for challenging pediatric infections.
Main Methods:
- Retrospective analysis of 91 pediatric patients treated with tigecycline between 2010 and 2018 at a tertiary care hospital.
- Data collection included patient demographics, clinical outcomes, and adverse events from pharmacy and medical records.
Main Results:
- Tigecycline was administered to children aged 7 months to 17.5 years, with 98.9% having predisposing factors for infection.
- Bacterial isolates showed a low tigecycline resistance rate of 3.9%.
- Only 2 out of 91 patients experienced adverse effects, indicating a favorable safety profile.
Conclusions:
- Tigecycline may be a safe and effective salvage therapy for pediatric nosocomial infections caused by multidrug-resistant bacteria.
- Its broad-spectrum activity against resistant pathogens makes it a valuable option in critical care settings with limited treatment choices.
What Is Known And Objective:
The frequency of multidrug-resistant bacterial infections is increasing worldwide. Tigecycline may be an important option for children with life-threatening nosocomial infections due to multidrug-resistant bacteria. However, there are few published data on the use of tigecycline in paediatric patients. By examining the results of tigecycline use in children, we aimed to draw attention to the fact that tigecycline may be an alternative in the treatment of resistant infections in children.
Methods:
Paediatric patients treated with tigecycline from 1 January 2010 to 31 October 2018 at Eskişehir Osmangazi University Medical Faculty, which is a tertiary hospital, were analysed retrospectively to assess the efficacy and safety of tigecycline treatment in children. Patients using tigecycline were identified using the pharmacy database. Clinical and laboratory data were obtained from the files.
Results And Discussion:
This study included 91 children aged 7 months to 17.5 years; 52 were female (57.1%). At least one predisposing factor was present in 98.9% of the patients. Fifty-one bacteria were isolated from 44 patients. The tigecycline resistance rate was 3.9%. Only 2 of 91 patients experienced one or more side effects of tigecycline. Tigecycline can be used as salvage therapy in resistant infections where options are limited, although definitive conclusions about the efficacy and safety of tigecycline in children cannot be reached.
What Is New And Conclusion:
Tigecycline may be a safe and important option in paediatric nosocomial infections due to resistant bacteria. Resistant bacterial infections have become more common in recent years, its treatment becomes a difficult problem. Tigecycline has a broad-spectrum antibacterial activity including resistant pathogens.
More Related Videos
Related Concept Videos
01:23Stringent Response in E. coli
01:28Acute Pyelonephritis II: Diagnostic Studies and Management